Six Teams to Study Managed Care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

Six research teams will receive a total of $8.5 million. The teams will be led by Jose Escarce, MD, PhD, of RAND, Santa Monica, Calif; Edward Guadagnoli, PhD, Harvard Medical School; Katherine Kahn, MD, University of California, Los Angeles; Tracy Lieu, MD, Kaiser Permanente of Northern California, Oakland; Barbara McNeil, MD; Harvard Medical School; and Elizabeth Shenkman, PhD, University of Florida, Gainesville.

The three sponsoring organizations are the Agency for Health Care Policy and Research (AHCPR) and the Health Resources and Services Administration, both parts of the HSS, and the American Association of Health Plans Foundation, which provides research for the nation’s largest managed care

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content